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ObjeCtive To systematically evaluate the effects of physical 
activity in adult patients after completion of main treatment 
related to cancer.
Design Meta-analysis of randomised controlled trials 
with data extraction and quality assessment performed 
independently by two researchers.
Data sOurCes PubmeD, CINAHL, and Google Scholar from 
the earliest possible year to September 2011. References 
from meta-analyses and reviews.
stuDy selection Randomised controlled trials that assessed 
the effects of physical activity in adults who had completed 
their main cancer treatment, except hormonal treatment.
results There were 34 randomised controlled trials, of 
which 22 (65%) focused on patients with breast cancer, 
and 48 outcomes in our meta-analysis. Twenty two studies 
assessed aerobic exercise, and four also included resistance 
or strength training. The median duration of physical activity 
was 13 weeks (range 3-60 weeks). Most control groups were 
considered sedentary or were assigned no exercise. Based 
on studies on patients with breast cancer, physical activity 
was associated with improvements in insulin-like growth 
factor-I, bench press, leg press, fatigue, depression, and 
quality of life. When we combined studies on different types 
of cancer, we found significant improvements in body mass 
index (BMI), body weight, peak oxygen consumption, peak 
power output, distance walked in six minutes, right handgrip 
strength, and quality of life. Sources of study heterogeneity 
included age, study quality, study size, and type and 
duration of physical activity. Publication bias did not alter 
our conclusions.
COnClusiOns Physical activity has positive effects 
on physiology, body composition, physical functions, 
psychological outcomes, and quality of life in patients after 
treatment for breast cancer. When patients with cancer other 
than breast cancer were also included, physical activity was 
associated with reduced BMI and body weight, increased 
peak oxygen consumption and peak power output, and 
improved quality of life.
Introduction
Cancer survivors who have successfully completed their 
primary cancer treatment often expect to resume their 
work or daily life at a level similar to that before the can‑
cer diagnosis. While cancer treatment has been shown to 
be effective in prolonging survival, it can be intensive and 
can lead to increased fatigue, decreased physical activ‑
ity, and a reduction in quality of life.
1‑3 In addition, these 
unwanted effects of treatment can be prolonged and hinder 
the patients’ return to normal life.
4‑6
Physical activity is a potentially appealing intervention 
that could alleviate sequelae related to cancer and assist 
patients in returning to the health status they had before 
treatment. A systematic review published in 2005 sum‑
marised the evidence supporting the recommendation 
of physical activity during and after treatment related to 
cancer
7; and a meta‑analysis published in 2006 reported 
more favourable outcomes when physical activity was car‑
ried out after treatment.
8 In a recent study published in 
2011, starting an exercise programme after the comple‑
tion of treatment was shown to be acceptable to over three 
quarters of patients.
9 Several randomised controlled trials 
have assessed the efficacy of physical activity on indicators 
of physical and mental health in patients after cancer treat‑
ment,
8 and these trials reported significant improvement 
after physical activity.
The effects of physical activity on cancer have been 
examined in nine meta‑analyses, with three focusing on 
breast cancer
10‑12 and six on any type of cancer.
8 
 13‑ 17 The 
six meta‑analyses on any cancer type did not uniformly 
examine sources of study heterogeneity,
14‑16 assess publi‑
cation bias,
14‑17 or limit inclusion of randomised control‑
led trials to those with physical activity intervention only 
after cancer treatment.
8 
 13 
 17 Moreover, more randomised 
controlled trials have been published since the publication 
of the last meta‑analysis in 2011.
18 We updated the most 
recent meta‑analysis by including studies published more 
recently and included only randomised controlled trials. 
Using data from randomised controlled trials, we evalu‑
ated the best current evidence for the effects of physical 
activity on physical functions, physiological parameters, 
body composition, psychosocial outcomes, and quality of 
life in adult patients after they had completed their main 
treatment related to cancer.
Methods
search strategy for identification of relevant studies
We identified relevant studies by systematically searching 
PubMed, which included Medline, CINAHL, and Google 
Scholar with the last search being in September 2011. The 
search terms used were (cancer OR tumour OR tumor OR neo‑
plasm OR carcinoma OR chemotherapy OR   radiotherapy OR 
bone marrow transplant) AND (physical activity OR   exertion 
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OR exercise therapy OR physical education OR physical train‑
ing OR physical fitness OR walking) AND (intervention OR 
trial OR adherence OR compliance OR patient compliance 
OR patient education OR health promotion OR health educa‑
tion OR health behavior OR health behaviour OR behavioral 
therapy OR behavioural therapy OR behavioral change OR 
behavioural change OR positive reinforcement OR cognitive 
therapy) AND (controlled clinical trial OR randomised OR 
randomized OR placebo OR randomly OR group). We also 
searched the Cochrane Library for systematic reviews and 
meta‑analyses on the effects of physical activity in cancer sur‑
vivors. The reference lists of all selected studies, systematic 
reviews, and meta‑analyses were then examined for relevant 
studies. We obtained the full papers of studies identified as 
potentially eligible based on the titles and abstracts, and two 
of the authors (JWCH and BPHH), who served as raters, inde‑
pendently confirmed their eligibility.
selection criteria
The studies included were those that adopted a randomised 
controlled trial design, included adult patients (aged ≥18), 
included patients diagnosed with cancer, involved patients 
who had completed their main treatment for cancer but 
might be still undergoing hormonal treatment, and assessed 
the effect of physical activity on health indicators.
Data extraction and methodological quality assessment
JWCH and BPHH independently extracted relevant data 
using a standardised Excel template. From each study, they 
extracted general study information, details of interven‑
tion and control groups, means and standard deviations 
of outcomes after the intervention, side effects, and com‑
pliance/adherence rates. The summary statistics, when 
not reported, were calculated when sufficient data were 
available. Any discrepancies between data extracted by the 
two raters were discussed and consensus was achieved. A 
biostatistician (DYTF) also checked all extracted statistics.
Two authors (JWCH and DYTF) independently assessed 
the methodological rigour of the selected studies using a 
quality assessment checklist developed by the Scottish Inter‑
collegiate Guidelines Network.
19 They assessed the internal 
validity of each selected study using 10 criteria and rated the 
overall quality on a scale according to the likelihood that 
each unmet criterion would alter the study conclusions: ++ 
(very unlikely), + (unlikely), and − (likely). The two review‑
ers met to compare their quality assessment results for each 
study; all discrepancies were discussed and resolved.
statistical analysis
We planned to assess the effects of physical activity on 
cancer outcomes (that is, rates of survival and recurrence), 
psychological outcomes, and physical outcomes. None of 
the eligible studies provided data on cancer outcomes, and 
some of the other outcomes were not assessed by multiple 
studies. We therefore performed a meta‑analysis on an out‑
come if it was assessed in at least two studies. For each out‑
come, we first assessed study heterogeneity with Cochrane’s 
χ
2 test, with P<0.10 indicating evidence of heterogeneity. 
The degree of heterogeneity was measured by the I
2 statis‑
tic, with I
2 ≥50% indicating substantial heterogeneity.
20 In 
the presence of heterogeneity, we searched for its sources 
by random effects meta‑regression. We considered the fol‑
lowing study characteristics for heterogeneity: study quality 
(++, +, and −), publication year, percentage of female par‑
ticipants, mean age of participants, number of subjects ana‑
lysed, duration of intervention, type of physical activity, and 
percentage of patients with breast cancer. Pooled estimates 
and their 95% confidence intervals were obtained with the 
random effects method.
21 Publication bias was also exam‑
ined with Egger’s linear regression method, with P<0.10 
taken as an indication of publication bias.
22
A random effects meta‑regression was performed in the 
SAS version 9.2 (SAS, NC) and the other meta‑analyses 
were conducted in Stata version 11 for Windows (StatCorp, 
TX). The nominal level of significance was 5% in all tests 
unless otherwise specified.
results
We identified 1505 records from the database search and 
387 additional records from other sources (fig 1). After 
screening, 54 articles met our inclusion criteria and we 
assessed their methodological quality. Of these, 39 articles 
from 34 studies had at least one common outcome, and 
there were sufficient data for inclusion in the meta‑analysis. 
Seven studies (21%) and two articles from another two stud‑
ies had not been included in previous meta‑analyses (table 
1).
23‑31 Twenty two studies (65%) included only patients 
with breast cancer, three (9%) included only patients with 
colorectal cancer, one (3%) included only patients with 
endometrial cancer, and the eight (27%) remaining included 
patients with different types of cancer. Three studies had 
more than one intervention group and thus contributed 
more than one comparison with their control groups to the 
meta‑analysis. Another two studies published both the full 
and subgroup analyses. Among 43 intervention‑control 
comparisons, the median number of patients analysed was 
93 (range 14‑641) with a mean age of 55 (39‑74). We used 
27 (63%) intervention‑control comparisons to assess the 
Records a￿er duplicates removed (n=￿￿￿￿)
Records screened by titles and abstracts (n=￿￿￿￿)
Full text articles assessed for eligibility (n=￿￿￿)
Articles included in qualitative synthesis (n=￿￿)
Records identi￿ed through
other sources (n= -￿)
Records identi￿ed through
database search (n=￿￿€￿)
Articles ( ￿ studies) included in meta-analysis (n= ƒ)
Records excluded (n=￿￿￿€)
Full text articles excluded (n=￿￿):
  Included patients on cancer treatment (n= ￿)
  Did not specify status of cancer treatment (n=￿)
  Did not examine e‡ect of physical activity (n=￿)
  Study protocols with no results (n=￿)
  Not randomised controlled trials for assessing
    e‡ect of physical activity (n=￿ )
  No group without physical activity (n=￿)
Fig 1 |  selection process of eligible randomised controlled 
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Study Di￿erence (￿￿% CI) Di￿erence (￿￿% CI) No % with
breast cancer
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Fig 2 |  association between physical activity and insulin-like growth factor-i (ng/ml) in patients with breast cancer
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table 1 | Characteristics of 34 randomised controlled trials included in meta-analysis of effect of physical activity in patients after treatment for cancer
study Cancer type
no of subjects 
analysed/
randomised mean (sD) age (years) no (%) of women*
Physical activity
study 
quality type
total duration 
(weeks) minutes/session/ week) Frequency each week intensity Control group
Segar,
53 1998  Breast 24/24 48.9 (7.6) 24 (100) Aerobic 10 30 (120) 4 >60% age predicted maximum heart rate Maintain sedentary lifestyle −
Burnham,
54 2002  Breast (83%), colon (17%) 18/21 53.6 (8.6) 15 (83)† Aerobic 10 14-32 (42-96) 3 Low (25-35% heart rate reserve); moderate (40-50% heart 
rate reserve) No exercise −
Courneya,
55 2003a  Breast 52/53 58.5 (5.5) 53 (100) Aerobic 15 15-35 (45-105) 3 70-75% maximum oxygen consumption No exercise +
Courneya,
56 2003b  Colorectal 93/102 60.3 (10.4) 39 (42)† Aerobic 16 20-30 (60-150) 3-5 65-75% age predicted maximum heart rate No exercise +
Fairey,
33 2003  Breast 53/53 59 (6) 53 (100) Aerobic 15 15-35 (45-105) 3 70-75% peak oxygen consumption No exercise ++
Dimeo,
57 2004 Lung (39%), gastric (17%), 
colorectal (45%) 72/72 57.6 (10.0) 19 (26) Aerobic 3 30 (150) 5 80% age predicted maximum heart rate Relaxation training +
Pinto,
58 2005  Breast 86/86 53.1 (9.7) 86 (100) Aerobic 12 10-20 (20-100) 2-5 Moderate Maintain usual exercise style +
Sandel,
59 2005  Breast 38/38 59.6 (11.5) 38 (100) Aerobic 12 Dance movement: 25-30 (25-
60); core exercise: NR 1-2 Not stated Maintain usual exercise style +
Thorsen,
60 2005 
Breast (42%), gynaecological 
(22%), lymphoma (23%), 
testicular (18%)
111/139 39.1 (8.4) 75 (68)† Individualised, depends on individual preference 14 >30 (>60) >2 Slightly strenuous to strenuous (Borg perceived exertion 
scale 13-15 (60-70% age predicted maximum heart rate)) Maintain usual exercise style +
Schmitz,
34 2005  Breast 81/85 53.0 (8.1) 85 (100) Weight/strength 24 60 (120) 2 NR No exercise +
Ahmed,
61 2006 Breast cancer related 
lymphoedema 45/85 52.0 (7.5) 85 (100) Weight/strength 24 60 (120) 2 NR No exercise −
Basen-Engquist,
62 2006  Breast 51/60 55.2 (11.3) 60 (100) Aerobic 24 NR NR NR Standard written materials for 
exercise −
Culos-Reed,
63 2006  Breast (85%), others (15%) 36/38 51.2 (10.3) 36 (95) Yoga/stretching 7 75 (NR) NR NR No exercise −
Herrero,
64 2006  Breast 16/20 50.5 (7.7) 20 (100) Aerobic + resistance training 8 90 (270) 3 Cycle: 80% age predicted maximum heart rate; resistance: 
progressively increased intensity Maintain sedentary lifestyle −
Daley,
65 2007  Breast 72/72 51.3 (8.6) 72 (100) Aerobic 8 50 (150) 3 Moderate (65-85% age predicted maximum heart rate) Maintain usual exercise style +
Demark-Wahnefried,
66 2007 Breast (56%), prostate (44%) 519/543 56.9 (10.8) 291 (56)† Aerobic, by an effective programme using social  
cognitive theory 40 NR NR NR Aerobic, by printed materials only −
Matthews,
67 2007  Breast 36/36 53.5 (10.6) 36 (100) Aerobic 12 20-40 (60-200) 3-5 Moderate (Borg perceived exertion scale 11-13) Maintain usual exercise style −
Vallance,
68 2007 Breast
169/190 57 (NR) 190 (100) Aerobic, by printed materials
12 30 (150) 5 Moderate/vigorous Aerobic, by standard 
recommendation − 173/190 57.5 (NR) 190 (100) Aerobic, by step pedometer
166/189 57.5 (NR) 189 (100) Aerobic, by printed materials + step pedometer
Yuen,
69 2007 Breast
15/15 54.0 (13.0) 15 (100) Aerobic 12 20-40 (60-120)
3 Fairly light to somewhat hard (Borg perceived exertion scale 
10-13) Maintain usual exercise style −
14/14 54.3 (11.9) 14 (100) Weight/Strength 12 NR
Bennett,
70 2007 Breast (75%) others (25%) 56/56 57.8 (10.2) 50 (89) Aerobic 24 30 (210) 7 Moderate Maintain usual exercise style ++
Ligibel,
71 2008  Breast 82/101 52.5 (9.0) 101 (100) Aerobic + Strength 16 Aerobic: 90 (90); strength: 50 
(100) Aerobic: 1; strength: 2 NR Maintain usual exercise style +
Milne,
72 2008  Breast 58/58 55.1 (8.2) 58 (100) Aerobic + resistance training 12 Aerobic: 20 (60); resistance: NR 3 NR Maintain usual exercise style +
Fillion,
73 2008 Breast 87/94 52.5 (9.9) 94 (100) Aerobic 4 Supervised: (60); home based: 
NR NR NR No exercise +
Mulero Portela,
23 2008‡ Breast
21/25 54.0 (12.7) 25 (100) Aerobic + resistance training, in Gymnasium 26 Walking: 30 (90); resistance: NR Walking: 3; Resistance: 2 Walking: 60-80% age predicted maximum heart rate; 
resistance: Borg perceived exertion scale 13-15 No exercise −
22/28 54.6 (12.4) 28 (100) Aerobic + resistance training, at home 26 Walking: 30 (90); resistance: NR Walking: 3; resistance: 2
Walking: somewhat hard to hard (Borg perceived exertion 
scale 12-16); resistance: Borg perceived exertion scale 
13-15
No exercise −
Von Gruenigen,
74 2008, Von 
Gruenigen,
24 2009‡ Endometrial 45/45 54.7 (8.6) 45 (100) Aerobic 24 > 45 (>225) 5 NR Written information on the benefits 
of physical activity +
Irwin,
32 2009 Irwin,
75 2009 Breast 68/75 56.0 (8.6) 75 (100) Aerobic 24 Gymnasium: 30 (90); home: 
30 (60) Gymnasium: 3 home: 2 Moderate Maintain usual exercise style +
Morey,
40 2009 Breast (45%), prostate (41%), 
colorectal (14%) 641/641 73.1 (5.0) 349 (54) Endurance/strength 60 Endurance: 30 (210); strength: 
15 (45) Endurance: 7; strength: 3 Not stated No exercise +
Rogers,
76 2009 Breast 39/41 53 (9) 41 (100) Aerobic 12 (150) NR Moderate No exercise +
Schmitz,
77 2009 Breast cancer related 
lymphoedema 139/141 56.5 (8.3) 141 (100) Weight/strength
52 90 (180) 2 Individualised; upper limb exercise, limited by onset of 
lymphoedema (stop exercise and then restart) Maintain usual exercise style
++
Speck,
78 2010 Breast cancer with or at risk for 
lymphoedema 234/295 56.5 (8.3) 295 (100) +
Schmitz,
25 2010‡ Breast cancer at risk of 
lymphoedema 134/154 55.0 (8.0) 154 (100) ++
Mehnert,
26 2011‡ Breast 58/63 51.9 (8.5) 63 (100) Aerobic 10 90 (180) 2 Moderate: 60% VO2 max Maintain usual exercise style +
LaStayo,
27 2011‡
Breast (55%), prostate (27.5%), 
colorectal (17.5%), lung (7.5%), 
lymphoma (2.5%)
40/49 74.0 (6.1) 25 (63)† Resistance 12 3-20 (9-60) 3 Fairly light to somewhat hard (Borg perceived exertion scale 
11-13) Maintain usual exercise style +
Kaltsatou,
28 2011‡ Breast 27/27 56.8 (4.1) 27 (100) Aerobic 12 60 (180) 3 Moderate (65-80% age predicted maximum heart rate) Maintain usual lifestyle −
Pinto,
29 2011‡ Colorectal 42/46 57.3 (9.7) 26 (57) Aerobic 12 30 (>150) >5 Moderate (64-76% age predicted maximum heart rate) Maintain usual lifestyle +
Janelsins,
30 2011‡ Breast 19/31 53.5 (8.6) 31 (100) Aerobic 12 60 (180) 3 Moderate Psychosocial therapy −
Bourke,
31 2011‡ Colon 17/18 69.1 (7.2) 6 (33) Aerobic + resistance training 12 Aerobic: 30 (90); resistance: NR Aerobic: 3 Resistance: 3 Aerobic: 55-85% age predicted maximum heart rate. 
Resistance: NR Maintain usual lifestyle −
NR=not reported. *Percentages of women based on number of patients randomised unless stated otherwise. †Percentages of women based on number of analysed patients. ‡Studies not included in previous meta-analyses.
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table 1 | Characteristics of 34 randomised controlled trials included in meta-analysis of effect of physical activity in patients after treatment for cancer
study Cancer type
no of subjects 
analysed/
randomised mean (sD) age (years) no (%) of women*
Physical activity
study 
quality type
total duration 
(weeks) minutes/session/ week) Frequency each week intensity Control group
Segar,
53 1998  Breast 24/24 48.9 (7.6) 24 (100) Aerobic 10 30 (120) 4 >60% age predicted maximum heart rate Maintain sedentary lifestyle −
Burnham,
54 2002  Breast (83%), colon (17%) 18/21 53.6 (8.6) 15 (83)† Aerobic 10 14-32 (42-96) 3 Low (25-35% heart rate reserve); moderate (40-50% heart 
rate reserve) No exercise −
Courneya,
55 2003a  Breast 52/53 58.5 (5.5) 53 (100) Aerobic 15 15-35 (45-105) 3 70-75% maximum oxygen consumption No exercise +
Courneya,
56 2003b  Colorectal 93/102 60.3 (10.4) 39 (42)† Aerobic 16 20-30 (60-150) 3-5 65-75% age predicted maximum heart rate No exercise +
Fairey,
33 2003  Breast 53/53 59 (6) 53 (100) Aerobic 15 15-35 (45-105) 3 70-75% peak oxygen consumption No exercise ++
Dimeo,
57 2004 Lung (39%), gastric (17%), 
colorectal (45%) 72/72 57.6 (10.0) 19 (26) Aerobic 3 30 (150) 5 80% age predicted maximum heart rate Relaxation training +
Pinto,
58 2005  Breast 86/86 53.1 (9.7) 86 (100) Aerobic 12 10-20 (20-100) 2-5 Moderate Maintain usual exercise style +
Sandel,
59 2005  Breast 38/38 59.6 (11.5) 38 (100) Aerobic 12 Dance movement: 25-30 (25-
60); core exercise: NR 1-2 Not stated Maintain usual exercise style +
Thorsen,
60 2005 
Breast (42%), gynaecological 
(22%), lymphoma (23%), 
testicular (18%)
111/139 39.1 (8.4) 75 (68)† Individualised, depends on individual preference 14 >30 (>60) >2 Slightly strenuous to strenuous (Borg perceived exertion 
scale 13-15 (60-70% age predicted maximum heart rate)) Maintain usual exercise style +
Schmitz,
34 2005  Breast 81/85 53.0 (8.1) 85 (100) Weight/strength 24 60 (120) 2 NR No exercise +
Ahmed,
61 2006 Breast cancer related 
lymphoedema 45/85 52.0 (7.5) 85 (100) Weight/strength 24 60 (120) 2 NR No exercise −
Basen-Engquist,
62 2006  Breast 51/60 55.2 (11.3) 60 (100) Aerobic 24 NR NR NR Standard written materials for 
exercise −
Culos-Reed,
63 2006  Breast (85%), others (15%) 36/38 51.2 (10.3) 36 (95) Yoga/stretching 7 75 (NR) NR NR No exercise −
Herrero,
64 2006  Breast 16/20 50.5 (7.7) 20 (100) Aerobic + resistance training 8 90 (270) 3 Cycle: 80% age predicted maximum heart rate; resistance: 
progressively increased intensity Maintain sedentary lifestyle −
Daley,
65 2007  Breast 72/72 51.3 (8.6) 72 (100) Aerobic 8 50 (150) 3 Moderate (65-85% age predicted maximum heart rate) Maintain usual exercise style +
Demark-Wahnefried,
66 2007 Breast (56%), prostate (44%) 519/543 56.9 (10.8) 291 (56)† Aerobic, by an effective programme using social  
cognitive theory 40 NR NR NR Aerobic, by printed materials only −
Matthews,
67 2007  Breast 36/36 53.5 (10.6) 36 (100) Aerobic 12 20-40 (60-200) 3-5 Moderate (Borg perceived exertion scale 11-13) Maintain usual exercise style −
Vallance,
68 2007 Breast
169/190 57 (NR) 190 (100) Aerobic, by printed materials
12 30 (150) 5 Moderate/vigorous Aerobic, by standard 
recommendation − 173/190 57.5 (NR) 190 (100) Aerobic, by step pedometer
166/189 57.5 (NR) 189 (100) Aerobic, by printed materials + step pedometer
Yuen,
69 2007 Breast
15/15 54.0 (13.0) 15 (100) Aerobic 12 20-40 (60-120)
3 Fairly light to somewhat hard (Borg perceived exertion scale 
10-13) Maintain usual exercise style −
14/14 54.3 (11.9) 14 (100) Weight/Strength 12 NR
Bennett,
70 2007 Breast (75%) others (25%) 56/56 57.8 (10.2) 50 (89) Aerobic 24 30 (210) 7 Moderate Maintain usual exercise style ++
Ligibel,
71 2008  Breast 82/101 52.5 (9.0) 101 (100) Aerobic + Strength 16 Aerobic: 90 (90); strength: 50 
(100) Aerobic: 1; strength: 2 NR Maintain usual exercise style +
Milne,
72 2008  Breast 58/58 55.1 (8.2) 58 (100) Aerobic + resistance training 12 Aerobic: 20 (60); resistance: NR 3 NR Maintain usual exercise style +
Fillion,
73 2008 Breast 87/94 52.5 (9.9) 94 (100) Aerobic 4 Supervised: (60); home based: 
NR NR NR No exercise +
Mulero Portela,
23 2008‡ Breast
21/25 54.0 (12.7) 25 (100) Aerobic + resistance training, in Gymnasium 26 Walking: 30 (90); resistance: NR Walking: 3; Resistance: 2 Walking: 60-80% age predicted maximum heart rate; 
resistance: Borg perceived exertion scale 13-15 No exercise −
22/28 54.6 (12.4) 28 (100) Aerobic + resistance training, at home 26 Walking: 30 (90); resistance: NR Walking: 3; resistance: 2
Walking: somewhat hard to hard (Borg perceived exertion 
scale 12-16); resistance: Borg perceived exertion scale 
13-15
No exercise −
Von Gruenigen,
74 2008, Von 
Gruenigen,
24 2009‡ Endometrial 45/45 54.7 (8.6) 45 (100) Aerobic 24 > 45 (>225) 5 NR Written information on the benefits 
of physical activity +
Irwin,
32 2009 Irwin,
75 2009 Breast 68/75 56.0 (8.6) 75 (100) Aerobic 24 Gymnasium: 30 (90); home: 
30 (60) Gymnasium: 3 home: 2 Moderate Maintain usual exercise style +
Morey,
40 2009 Breast (45%), prostate (41%), 
colorectal (14%) 641/641 73.1 (5.0) 349 (54) Endurance/strength 60 Endurance: 30 (210); strength: 
15 (45) Endurance: 7; strength: 3 Not stated No exercise +
Rogers,
76 2009 Breast 39/41 53 (9) 41 (100) Aerobic 12 (150) NR Moderate No exercise +
Schmitz,
77 2009 Breast cancer related 
lymphoedema 139/141 56.5 (8.3) 141 (100) Weight/strength
52 90 (180) 2 Individualised; upper limb exercise, limited by onset of 
lymphoedema (stop exercise and then restart) Maintain usual exercise style
++
Speck,
78 2010 Breast cancer with or at risk for 
lymphoedema 234/295 56.5 (8.3) 295 (100) +
Schmitz,
25 2010‡ Breast cancer at risk of 
lymphoedema 134/154 55.0 (8.0) 154 (100) ++
Mehnert,
26 2011‡ Breast 58/63 51.9 (8.5) 63 (100) Aerobic 10 90 (180) 2 Moderate: 60% VO2 max Maintain usual exercise style +
LaStayo,
27 2011‡
Breast (55%), prostate (27.5%), 
colorectal (17.5%), lung (7.5%), 
lymphoma (2.5%)
40/49 74.0 (6.1) 25 (63)† Resistance 12 3-20 (9-60) 3 Fairly light to somewhat hard (Borg perceived exertion scale 
11-13) Maintain usual exercise style +
Kaltsatou,
28 2011‡ Breast 27/27 56.8 (4.1) 27 (100) Aerobic 12 60 (180) 3 Moderate (65-80% age predicted maximum heart rate) Maintain usual lifestyle −
Pinto,
29 2011‡ Colorectal 42/46 57.3 (9.7) 26 (57) Aerobic 12 30 (>150) >5 Moderate (64-76% age predicted maximum heart rate) Maintain usual lifestyle +
Janelsins,
30 2011‡ Breast 19/31 53.5 (8.6) 31 (100) Aerobic 12 60 (180) 3 Moderate Psychosocial therapy −
Bourke,
31 2011‡ Colon 17/18 69.1 (7.2) 6 (33) Aerobic + resistance training 12 Aerobic: 30 (90); resistance: NR Aerobic: 3 Resistance: 3 Aerobic: 55-85% age predicted maximum heart rate. 
Resistance: NR Maintain usual lifestyle −
NR=not reported. *Percentages of women based on number of patients randomised unless stated otherwise. †Percentages of women based on number of analysed patients. ‡Studies not included in previous meta-analyses.
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meta-analysis of body composition
There was no study heterogeneity for any of the six body 
parameters assessed. Physical activity was associated with 
slightly reduced body mass index (BMI) (−0.4, −0.6 to −0.2; 
P<0.01) and body weight (−1.1 kg, −1.6 to −0.6 kg; P<0.001) 
(fig 3) than the control condition (table 4). Publication bias 
was evident only for the waist:hip ratio (P=0.06) because 
of one of the three studies reporting a more substantial 
reduction than the other two. The effect on waist:hip ratio, 
however, remained insignificant after we removed this study 
from the meta‑analysis. Forest plots for all markers of body 
composition can be found on bmj.com.
meta-analysis of physical functions
Except for bench press and leg press, which were assessed 
only in patients with breast cancer, all other physical func‑
tions were assessed in studies on several types of cancer. 
Substantial heterogeneity was found for leg press, left 
handgrip, and right handgrip (table 2). The higher qual‑
ity study reported a smaller increase in leg press, whereas 
the studies involving older patients or published in recent 
years reported larger increases in left handgrip and right 
handgrip. Otherwise, neither heterogeneity nor publica‑
tion bias was detected (P≥0.12). Physical activity was 
associated with significantly increased peak oxygen con‑
sumption (2.2 mL/kg/min, 1.0 to 3.4; P<0.01), peak power 
output (21.0 W, 13.0 to 29.1; P<0.01), the distance walked 
in six minutes (29 m, 4 to 55; P=0.03; fig 4), bench press 
effects of an aerobic exercise programme, and six (14%) 
studies had patients who additionally underwent resistance 
or strength training. The other comparisons were made for 
strength or tailored training based on preference of patients. 
The median duration of the physical activity intervention 
was 13 weeks (range 3‑60). Only 13 studies stated the inten‑
sity level of physical activity; 11 were of moderate intensity 
and two were of vigorous intensity. Most control groups 
were considered sedentary or were assigned no exercise. We 
assessed 48 outcomes at least twice in the 43 intervention‑
control comparisons (tables 2 and 3).
meta-analysis of physiological markers
Physiological markers were assessed only in breast can‑
cer studies. Four physiological markers were included in 
the meta‑analysis: insulin‑like growth factor‑I, insulin, 
glucose, and homeostatic model assessment. There was 
no study heterogeneity in these physiological markers, 
with I
2 being 28% at most, and there was no evidence of 
publication bias (P≥0.47). In three studies, of which two 
assessed aerobic exercise and the third assessed weight/
strength training, physical activity was associated with sig‑
nificantly reduced insulin‑like growth factor‑I (−12.0 ng/
mL, 95% confidence interval −23.3 to −0.5; P=0.04; fig 2) 
more than the controls) (table 4). No effect was shown for 
the other physiological markers. Forest plots for all physi‑
ological markers can be found on bmj.com.
table 2 | study heterogeneity and sources of heterogeneity by meta-regression analysis* of effect of physical activity in patients after treatment for cancer. meta-
regression performed for all outcomes but source of heterogeneity identified only for leg press and left and right handgrip  
Outcomes(units or plausible ranges) no of comparisons Common characteristics (level)
heterogeneity
i
2 (%) P value
Physiological markers
Insulin-like growth factor-I 
(ng/mL) 4
30 32-34 Cancer type (breast) 0 0.70
Insulin (pmol/L) 4
30 33 34 71 Cancer type (breast) 18 0.30
Glucose (mmol/L) 3
33 34 71 Cancer type (breast) 28 0.25
Homeostatic model 
assessment 2
34 71 Cancer type (breast) 0 0.67
body composition
% Body fat 11
25 34 54 58 64 65 67 71 75-77 — 0 0.74
Body fat (kg) 6
25 30 34 64 67 77 Cancer type (breast) 0 0.77
BMI 16
23 25 30 31 34 40 55 56 58 65 66 71 75-77 — 0 0.50
Waist circumference (cm) 3
34 71 75 Quality (+); cancer type (breast) 0 0.58
Waist:hip ratio 3
31 71 76 — 0.5 0.37
Lean mass (kg) 7
25 30 34 64 67 75 77 Cancer type (breast) 0 0.97
Weight (kg) 14
25 30 31 34 40 54 55 63 64 67 71 74 75 77 — 0 0.77
Physical functions
Peak heart rate (beats/min) 3
55 63 64 — 24 0.27
Peak oxygen consumption 
(mL/kg/min) 7
26 29 54 55 60 64 73 — 18 0.29
Peak power output (W) 3
55 57 64 — 0 0.56
Six minute walk (m) 5
27 28 62 69 — 20 0.29
Bench press (kg, 1 repetition 
maximum) 3
25 61 78 Cancer type (breast) 54 0.12
Leg press (kg, 1 repetition 
maximum) 3
25 61 78 Cancer type (breast) 71 0.03
Left handgrip (kg) 3
28 63 76 — 71 0.03
Right handgrip (kg) 5
23 28 63 76 — 56 0.06
Sit and reach (cm) 2
54 63 Quality (−) 0 0.32
*Multivariable meta-regression. Source of heterogeneity for leg press: quality −20.4 (95% CI −36.2 to −4.6), P=0.01 (confounder: one grade increase); source of heterogeneity for left handgrip: age 2.3 (0.6 to 4.0), 
P=0.01 (confounder year 2.1 (0.3 to 3.8), P=0.02); source of heterogeneity for right handgrip: year 1.8 (0.4 to 3.2), P=0.01 (confounder age 1.4 (0.2 to 2.7), P=0.03).BMJ | research  7 of 14
research
core quality of life questionnaire and the two hospital anxi‑
ety and depression scales (table 3). Measured by the revised 
Piper fatigue scale, physical activity was associated with 
slightly reduced fatigue (−1.0, −1.8 to −0.1; P=0.03; fig 
5) in three comparisons from two studies on breast cancer 
compared with the control (table 5). Measured by the Beck 
depression inventory, physical activity was associated with 
reduced depression (−4.1, −6.5 to −1.8; P<0.01) in survi‑
vors of mixed types of cancer, which was of near clinical 
weight (6 kg, 4 to 8; P<0.01), leg press weight (19 kg, 9 to 
28; P<0.01), and right handgrip strength by 3.5 kg, 0.3 to 
6.7; P=0.03) (table 4). Forest plots for all markers of physi‑
cal function can be found on bmj.com. 
meta-analysis of psychological outcomes
There was no heterogeneity in any of the psychological 
outcomes except for fatigue measured by the European 
  Organization for Research and Treatment of Cancer (EORTC) 
table 3 | study heterogeneity and sources of heterogeneity by meta-regression analysis of effect of physical activity in patients after treatment for cancer
Outcomes(units or plausible 
ranges)
no of 
comparisons
Common 
characteristics 
(level)
heterogeneity multivariable meta-regression*
i
2 (%) P value
source of heterogeneity 
[confounder] estimate (95% Ci) P value
Psychological outcomes
FACT-fatigue (0-52) 8
24 29 31 55 56 68 — 0 0.86 — — —
PFS-fatigue (0-10) 3
65 69
Publication year 
(2007); cancer type 
(breast)
0 0.64 — — —
EORTC-fatigue (0-100) 2
57 60 Quality (+) 75 0.05 Any one of sources except quality† — —
BDI (0-63) 4
24 28 53 65
Physical activity 
(aerobic); sex 
(female)
47 0.13 — — —
HADS-depression (0-21) 2
26 60 Quality (+) 76 0.04 Any one of sources except quality† — —
HADS-anxiety (0-21) 2
26 60 Quality (+) 78 0.03 Any one of sources except quality† — —
POMS-total mood disturbance    2
58 63 — 53 0.15 — — —
Quality of life outcomes
EORTC:
  Physical function (0-100) 2
57 60 Quality (+) 0 0.49 — — —
  Emotional function (0-100) 3
57 60 63 — 77 0.01 Quality: + v – [study size]
−17.4 (−28.9 
to −5.8) [−0.22 
(−0.37 to −0.06)]
0.003 [0.006]
  Total (0-100) 3
57 60 63 — 70 0.04 Quality: + v – [study size]
−16.5 (−29.2 
to −3.8) [−0.18 
(−0.34 to −0.08)]
0.01 [0.03]
FACT:
  Physical wellbeing (0-28) 6
24 55 56 65 72 76 Quality (+) 92 <0.001 Aerobic + resistance v aerobic 8.4 (6.3 to 10.5) <0.001
  Emotional wellbeing (0-24) 6
24 55 56 65 72 76 Quality (+) 61 0.03 Aerobic + resistance v aerobic 2.8 (0.9 to 4.7) 0.01
  Social/family wellbeing 
(0-28) 6
24 55 56 65 72 76 Quality (+) 15 0.32 — — —
  Functional wellbeing (0-28)  6
24 55 56 65 72 76 Quality (+) 93 <0.001 Aerobic + resistance v aerobic 9.6 (7.1 to 12.1) <0.001
  Breast (0-36) 4
55 65 72 76 Quality (+); cancer 
type (breast) 78 0.003
Aerobic + resistance v aerobic 5.3 (1.9 to 8.7) 0.002
Treatment duration [age]
−0.8 (−1.4 to −0.1) 
[−0.7 (−1.3 to 
−0.1)]
0.02 [0.03]
  Breast total (0-140) 10
23 55 59 65 68 72 76 Cancer type (breast) 86 <0.001 Aerobic + resistance v aerobic 24.4 (17.9 to 30.9) <0.001
  Colorectal total (0-136) 3
29 31 56 Cancer type 
(colorectal) 0 0.72 — — —
  General total (0-108) 7
24 55 56 65 66 72 76 — 92 <0.001 Aerobic + resistance v aerobic 22.1 (16.7 to 27.4) <0.001
SF-36:
  Physical function (0-100) 2
40 62 — 0.0 0.51 — — —
  Role physical (0-100) 2
40 62 — 56 0.13 — — —
  Bodily pain (0-100) 2
40 62 — 54 0.14 — — —
  General health (0-100) 2
40 62 — 76 0.04 Any one of sources† — —
  Vitality (0-100) 2
40 62 — 0 0.82 — — —
  Social function (0-100) 2
40 62 — 0 0.45 — — —
  Role emotion (0-100) 2
40 62 — 0 0.82 — — —
  Mental health (0-100) 2
40,62 — 0 0.64 — — —
SF physical component scale 
(0-100)‡ 4
59 73 78 — 55 0.09 Age −0.9 (−1.8 to 
−0.04) 0.04
SF mental component scale 
(0-100)†‡ 4
59 73 78 — 39 0.18 — — —
BDI=Beck depression inventory; EORTC=European Organization for Research and Treatment of Cancer; FACT=functional assessment of cancer therapy; HADS=hospital anxiety and depression scale; PFS=revised 
Piper fatigue scale; POMS=profile of mood states; SF-36=short form-36.                
*Values in square brackets correspond to those confounders.
†As there were only two studies.
‡Two studies used SF-36 and one used SF-12.8 of 14  BMJ | research
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Fig 4 |  association between 
physical activity and distance 
(m) walked in six minutes in 
patients with cancer
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insulin‑like growth factor‑I, BMI, body weight, fatigue, 
and depression; it is also associated with increased peak 
oxygen consumption, peak power output, distance walked 
in six minutes, bench and leg press weight, right handgrip 
strength, and quality of life in the physical function, social 
function, and mental health domains. Our meta‑analysis 
featured both exploration of sources of heterogeneity and 
assessment of publication bias that assesses the efficacy 
of physical activity on health indicators in patients with 
any type of cancer after completion of their primary cancer 
treatment. We reviewed 48 outcomes reported from 34 ran‑
domised controlled trials in patients with cancer. The effects 
were clinically important to physical functions and quality 
of life. We found substantial study heterogeneity, which was 
attributed to study quality and size, patients’ age, and type 
and duration of physical activity.
Based on data from four randomised controlled trials in 
breast cancer,
30 
 32‑ 34 physical activity was associated with 
significantly reduced serum concentration of insulin‑like 
growth factor‑I, despite insignificant results being reported 
in the primary studies. This was because of the increased 
precision resulting from combining different studies. A 
recent meta‑analysis that pooled three of the studies we 
included also reported a small reduction in insulin‑like 
growth factor‑I.
16 Another meta‑analysis that examined 
physiological changes after exercise reported that the effect 
of physical activity was insignificant.
14 That meta‑analysis, 
however, combined different physiological parameters 
and might have included non‑randomised studies. Raised 
concentration of insulin‑like growth factor‑I is known to 
be associated with an increased risk of colorectal cancer.
35 
Thus, a significant reduction in insulin‑like growth factor‑
I by aerobic or weight/strength training could potentially 
imply a reduced risk of cancer recurrence. However, there 
was no clear trend of an effect of physical activity on blood 
importance. No publication bias was found in any of the 
psychological outcomes (P≥0.82). Forest plots for all mark‑
ers of psychological outcome can be found on bmj.com.
meta-analysis of quality of life outcomes
There were 21 quality of life domains included in the meta‑
analysis and 10 of them exhibited heterogeneity (table 3). 
Identified sources of heterogeneity were study quality, 
sample size, type and duration of physical activity, and 
age. Study quality was strongly and positively associated 
with sample size, with smaller studies being associated 
with larger effects of physical activity on emotional func‑
tion and total domains of the European Organization for 
Research and Treatment of Cancer. One study in patients 
with breast cancer found that aerobic plus resistance train‑
ing was significantly more effective than aerobic training 
alone on physical, emotional, and functional wellbeing, 
breast concerns, breast total, and general total scores on 
the functional assessment of cancer therapy. In addition, 
the effect of physical activity on breast concerns was sig‑
nificantly greater in younger patients. The age effect, how‑
ever, was confounded by the duration of physical activity.
In mixed types of cancer survivors, physical activity 
improved the SF‑36 physical function scores by 3.0 points 
(0.6 to 5.3; P=0.01), social function by 3.4 points (0.4 to 
6.4; P=0.03) and mental health by 2.4 points (0.7 to 4.1; 
P=0.01) (fig 6) compared with the control group (table 5). 
No publication bias was found in any of the quality of life 
domains (P=0.21). Forest plots for all markers of quality of 
life can be found on bmj.com.
Discussion
effects of physical activity
In patients who have completed treatment for cancer, 
physical activity is associated with significantly reduced 
table 4 | Pooled effects of physical activity in patients after treatment for cancer
Outcomes (units or plausible ranges) Pooled estimate (95% Ci) P value minimal clinically important difference
Physiological markers
Insulin-like growth factor-I (ng/mL) −12.0 (−23.3 to −0.5) 0.04 NA
Insulin (pmol/L) 0.72 (−12.0 to 13.5) 0.91 NA
Glucose (mmol/L) −0.04 (−0.32 to 0.24) 0.77 NA
Homeostatic model assessment  −0.08 (−0.50 to 0.34) 0.71 NA
body composition
% Body fat −0.8 (−1.7 to 0.02) 0.06 NA
Body fat (kg) −1.5 (−3.3 to 0.3) 0.10 NA
BMI −0.4 (−0.6 to −0.2) <0.01 NA
Waist circumference (cm) −0.7 (−4.2 to 2.8) 0.69 NA
Waist:hip ratio −0.01 (−0.04 to 0.02) 0.59 NA
Lean mass (kg) 0.6 (−0.5 to 1.7) 0.26 NA
Weight (kg) −1.1 (−1.6 to −0.6) <0.01 NA
Physical functions
Peak heart rate (beats/min) −0.5 (−9.5 to 8.5) 0.91 NA
Peak oxygen consumption (mL/kg/min) 2.2 (1.0 to 3.4) <0.01 NA
Peak power output (W) 21.0 (13.0 to 29.1) <0.01 4
79
Six minute walk (m) 29 (4 to 55) 0.03 25
80
Bench press (kg, 1 repetition maximum) 6 (4 to 8) <0.01 NA
Leg press (kg, 1 repetition maximum) 19 (9 to 28) <0.01 NA
Left handgrip (kg) 4.3 (−1.5 to 10.2) 0.15 6.2
81
Right handgrip (kg) 3.5 (0.3 to 6.7) 0.03 6.2
81
Sit and reach (cm) 2 (−3 to 8) 0.36 NA
NA=not available.10 of 14  BMJ | research
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table 5 | Pooled effects of physical activity in patients after treatment for cancer
Outcomes(units or plausible ranges) Pooled estimate (95% Ci) P value minimal clinically important difference
Psychological outcomes
FACT-fatigue (0-52) 0.4 (−0.8 to 1.6) 0.50 3-4
82
PFS-fatigue (0-10) −1.0 (−1.8 to −0.1) 0.03 NA
EORTC-fatigue (0-100) 17.1 (−0.7 to 34.9) 0.06 5
83
BDI (0-63) −4.1 (−6.5 to −1.8) <0.01 5
84
HADS-depression (0-21) −0.5 (−2.8 to 1.7) 0.64 1.40
85
HADS-anxiety (0-21) −0.7 (−3.4 to 2.1) 0.63 1.32
85
POMS-total mood disturbance   −7.5 (−16.0 to 1.0) 0.09 7.4
86
Quality of life outcomes
EORTC-physical function (0-100):
  All −1.2 (−5.1 to 2.6) 0.54 5
83
EORTC-emotional function (0-100):
  All 1.5 (−9.8 to 12.7) 0.80 4.3
86
  Study quality + −4.4 (−9.9 to 1.1) 0.12 —
  Study quality – 13.0 (2.8 to 23.2) — —
EORTC-total (0-100):
  All 3.7 (−5.2 to 12.6) 0.41 4
83
  Study quality + −0.8 (−5.4 to 3.9) 0.75 —
  Study quality – 15.7 (4.0 to 27.5) — —
FACT-physical wellbeing (0-28):
  All 1.4 (−1.7 to 4.5) 0.39 2-3
82
  Assessed aerobic exercise 0.0 (−1.1 to 1.1) 1.00 —
  Assessed aerobic+resistance 8.4 (6.5 to 10.3) — —
FACT-emotional wellbeing (0-24):
  All 0.7 (−0.6 to 1.9) 0.31 2-3
82
  Assessed aerobic exercise 0.1 (−0.8 to 1.1) 0.80 —
  Assessed aerobic+resistance 2.9 (1.2 to 4.6) — —
FACT-social/family wellbeing (0-28):
  All 0.7 (−0.2 to 1.6) 0.14 2-3
82
FACT-functional wellbeing (0-28):
  All 1.9 (−1.9 to 5.8) 0.33 2-3
82
  Assessed aerobic exercise 0.2 (−1.5 to 1.9) 0.82 —
  Assessed aerobic+resistance 9.7 (7.6 to 11.8) — —
FACT-breast (0-36):
  All 1.9 (−1.6 to 5.4) 0.28 2-3
87
  Assessed aerobic exercise 0.6 (−2.6 to 3.8) 0.73 —
  Assessed aerobic+resistance 5.6 (2.8 to 8.4) — —
FACT-breast total (0-140):
  All 7.6 (0.6 to 14.5) 0.03 5-6
87
  Assessed aerobic exercise 2.5 (−0.9 to 6.0) 0.15 —
  Assessed aerobic+resistance 27.9 (21.5 to 34.3) — —
FACT-colorectal total (0-136):
  All −1.6 (−6.2 to 2.9) 0.48 5-8
88
FACT-general total (0-108):
  All 4.2 (−3.1 to 11.5) 0.26 3-7
87
  Assessed aerobic exercise 0.7 (−2.4 to 3.8) 0.65 —
  Assessed aerobic+resistance 22.3 (17.3 to 27.3) — —
SF-36 (all 0-100):
  Physical function 3.0 (0.7 to 5.3) 0.01 3
89
  Role physical 6.1 (−4.1 to 16.2) 0.24 3
89
  Bodily pain 4.3 (−0.6 to 9.2) 0.08 3
89
  General health 5.8 (−1.2 to 13.) 0.12 3
89
  Vitality 2.1 (−0.4 to 4.5) 0.10 3
89
  Social function 3.4 (0.4 to 6.4) 0.03 3
89
  Role emotion −0.01 (−3.7 to 3.6) 1.00 3
89
  Mental health 2.4 (0.7 to 4.1) 0.01 3
89
SF Physical component scale (0-100)† 1.2 (−1.9 to 4.4) 0.44 3
89
SF Mental component scale (0-100)† 0.4 (−2.3 to 3.2) 0.76 3
89
BDI=Beck depression inventory; EORTC=European Organization for Research and Treatment of Cancer; FACT=functional assessment of cancer therapy; HADS=hospital anxiety and depression scale; NA=not 
available; PFS=revised Piper fatigue scale; POMS=profile of mood states; SF-36=short form 36.
†Two studies used SF-36 and one used SF-12.BMJ | research  11 of 14
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larger improvements on both the physical and functional 
wellbeing scales of the functional assessment of cancer 
therapy than studies that examined aerobic exercise alone. 
The effect of the type of physical activity was not examined 
for the European Organization for Research and Treatment of 
Cancer and SF‑36 scales because they were not measured in 
studies that used aerobic plus resistance training. The signifi‑
cant improvement shown in the physical function scale of the 
SF‑36 survey is probably because of the inclusion of a recent 
large study.
28 For the mental domain, there was a significant 
improvement in the emotional wellbeing scale of the func‑
tional assessment of cancer therapy and the mental health 
scale of the SF‑36 survey in studies of breast cancer survivors. 
The European Organization for Research and Treatment of 
Cancer also has a scale for emotional function, but no sig‑
nificant effect was found except in one study with the small‑
est sample size. For the social domain, clinically important 
improvement was found only in the social function scale of 
the SF 36 survey but not in the social/family wellbeing scale 
of the functional assessment of cancer therapy. This could 
be because of the inclusion of a large study.
40 These findings 
have not been reported in other meta‑analyses.
limitations of selected studies and previous meta-analyses
The intensity of physical activity could play an important 
role in its effects.
41 
 42 The intensity levels in interventions 
in the selected studies, however, were not consistently 
reported, which made it difficult to assess their influence 
on study heterogeneity. Nevertheless, the significantly 
larger effects of aerobic plus resistance training than aerobic 
training alone might indicate a potential benefit of higher 
intensity. Standardisation of reporting of exercise intensity, 
perhaps with a new method of considering both the gas 
exchange threshold and the conventional maximal oxygen 
uptake,
43 in future randomised controlled trials of physical 
activity in patients with cancer is desirable.
The standardised effect sizes of the outcomes across 
studies were measured by different methods or measure‑
ment scales in all but one meta‑analysis. This resulted in 
previously unidentified important effects of physical activ‑
ity on quality of life. Four meta‑analyses that assessed the 
effects of physical activity in patients of any cancer type 
included both randomised and non‑randomised controlled 
trials.
8 
 13 
 14 
 16 This might have increased study heterogene‑
ity or publication bias. In addition, although these meta‑
analyses reported that physical activity improved physical 
function or cardiorespiratory fitness, the measures used to 
define these two health indicators were unclear. Only one 
meta‑analysis clearly described physical function as a set 
of aerobic capacity or timed walking distance.
13 Although 
these meta‑analyses standardised the mean difference 
between groups before pooling the estimates, the esti‑
mates represented a combination of different outcomes, 
such as peak oxygen consumption and distance walked in 
six minutes, which measured distinct domains of physical 
performance. The same concern applies to other health out‑
comes, such as fatigue, which might have been measured 
with different scales. In the sequel, although the other two 
meta‑analyses included randomised controlled trials only, 
they also pooled different measures of fatigue.
15 
 17 Mixing 
studies with outcomes measured with different instruments 
insulin, glucose, and homeostatic model assessment levels.
BMI and body weight were found to be slightly but signifi‑
cantly reduced after physical activity intervention in studies 
that included patients with any cancer or breast cancer. The 
same result was found in the most recent meta‑analysis, 
which also reported significant but not clinically important 
effects.
16 None of the other body parameters was significantly 
improved by physical activity. This finding is consistent with 
the literature, although previous meta‑analyses have shown 
that percentage of body fat and lean body mass were signifi‑
cantly improved.
11 
 12 
 16 These meta‑analyses, however, also 
included studies assessing physical activity during cancer 
treatment or did not show a clinically important effect.
Physical activity after completion of cancer treatment had 
clear benefits for many physical functions, including peak 
oxygen consumption, peak power output, distance walked 
in six minutes, and bench and leg press weights. Except for 
those of bench and leg presses, these findings have also 
been consistently reported in all other meta‑analyses.
8 
 10‑ 14 
The only meta‑analysis that reported unstandardised effects 
showed a slightly larger effect than ours on peak oxygen con‑
sumption (3.39 mL/kg/min, 1.67 to 5.10 mL/kg/min) and 
distance walked in six minutes (35 m, 13 to 58 m).
11 That 
meta‑analysis, however, included only studies on patients 
with breast cancer, who might carry out physical activity 
during and after treatment.
A significant but small reduction in fatigue was observed 
in breast cancer studies using the revised Piper fatigue 
scale but not in studies on any cancer using either of the 
other two fatigue scales. Both the revised Piper fatigue 
scale and functional assessment of cancer therapy‑fatigue 
have been shown to perform satisfactorily in measuring 
cancer related fatigue.
36 
 37 The fatigue scale by the Euro‑
pean Organization for Research and Treatment of Cancer 
has also been shown to have satisfactory psychometric per‑
formance but it is not specific to cancer related fatigue.
38 
The revised Piper fatigue scale, however, was primarily 
used in patients with breast cancer and thus has limited 
generalisability to patients with other cancers.
39 Neverthe‑
less, it measures the current, rather than recalled, fatigue 
level of patients and so could be more sensitive in assessing 
the acute short term effects of physical activity. Only three 
meta‑analyses have concluded that physical activity had 
significant effects on relieving fatigue.
15‑17 They reported 
at least small to moderate effects of physical activity. 
Although the two studies that used the fatigue scale from 
the European Organization for Research and Treatment of 
Cancer showed significant improvement, their reported 
effects were largely different. This led to a large variation 
that resulted in an insignificant pooled random effects esti‑
mate. The same phenomenon was also observed for the 
total mood scale of the profile of mood states. Depression 
measured by the Beck depression inventory, however, was 
significantly reduced at a level of near clinical importance. 
This finding has not been reported in other meta‑analyses.
Quality of life in patients with cancer has been assessed 
in the physical, mental, social, and overall quality of life 
domains by using four common instruments. For the physi‑
cal domain, only the SF‑36 survey showed a significant 
improvement of marginal clinical importance. The study of 
aerobic plus resistance exercise, however, found significantly 12 of 14  BMJ | research
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interventions in our selected studies would limit assess‑
ment of the long term benefits of physical activity.
implications for research and practice
Future research should focus on cancers other than breast 
cancer. Moreover, a standardised use of outcome meas‑
ures and assessment of the intensity of physical activity 
are desirable and important in future randomised control‑
led trials to facilitate more reliable and valid synthesis of 
results from different studies.
Conclusions
Based on our review of 48 outcomes reported from 34 ran‑
domised controlled trials in patients with cancer, physical 
activity was shown to be associated with clinically impor‑
tant positive effects on physical functions and quality of 
life in patients who had completed their treatment for can‑
cer. All of these benefits were applicable to patients with 
breast cancer. When we included studies of other types 
such as prostate, gynaecological, colorectal, gastric, and 
lung cancers, there was evidence of clinically important 
benefits on peak oxygen consumption, peak power out‑
put, and quality of life, which included physical and social 
functioning domains. Further randomised controlled tri‑
als on patients with cancers other than of the breast are 
needed to further assess the efficacy of physical activity 
on other health outcomes.
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has long been known to potentially pose a threat to the valid‑
ity of the resulting conclusions, although researchers might 
still statistically combine diverse study outcomes.
44 Impor‑
tantly, it is difficult to interpret the resulting pooled estimate 
because it represents a mixture of outcomes under distinct 
domains.
45 Indeed, the Cochrane Handbook has generally 
emphasised the importance of due consideration when 
combining different variables, and researchers should not 
combine outcomes that are too diverse.
46 These suboptimal 
meta‑analytic protocols were probably used because of the 
limited number of relevant randomised controlled trials in 
the literature. Thus, this meta‑analysis included only ran‑
domised controlled trials and pooled studies for each out‑
come measured on the same scale.
limitations
We included only published randomised controlled tri‑
als in our meta‑analysis, which could have increased the 
risk of publication bias by not including non‑randomised 
studies or unpublished studies. The risk of publication 
bias might have been further increased by searching only 
three electronic databases and not contacting other experts 
for possible inclusion of more relevant studies. Non‑ran‑
domised studies had been included in previous meta‑
analyses because of the lack of published randomised 
controlled trials.
8 
 13 
 14 
 16 Non‑randomised studies, how‑
ever, can overestimate treatment effects by 30‑41%
47; thus, 
their inclusion in our study might have yielded overly opti‑
mistic effects of physical activity. In addition, unpublished 
studies, such as abstracts or reports, often report smaller 
treatment effects,
48 are often of poor quality, and do not 
provide sufficient data for statistical synthesis. Further‑
more, we carefully examined all relevant meta‑analyses, 
including the most recent three published in 2010 and 
2011. We were not aware of any relevant unpublished 
studies when this study was conducted. Moreover, most 
outcomes did not exhibit publication bias; when it was 
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